A Phase 3 Study of Tezacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis , Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Об исследовании

This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

Открыть NCT02412111 на ClinicalTrials.gov →

Связанные материалы

Связанные исследования